Whooping cough explained

Whooping cough
Synonyms:Pertussis, 100-day cough
Field:Infectious disease
Symptoms:Runny nose, fever, cough
Complications:Vomiting, broken ribs, exhaustion
Duration:~ 3 months
Causes:Bordetella pertussis (spread through the air)
Diagnosis:Nasopharyngeal swab
Prevention:Pertussis vaccine
Treatment:Antibiotics (if started early)
Frequency:16.3 million (2015)
Deaths:58,700 (2015)

Whooping cough, also known as pertussis or the 100-day cough, is a highly contagious, vaccine-preventable bacterial disease.[1] Initial symptoms are usually similar to those of the common cold with a runny nose, fever, and mild cough, but these are followed by two or three months of severe coughing fits. Following a fit of coughing, a high-pitched whoop sound or gasp may occur as the person breathes in. The violent coughing may last for 10 or more weeks, hence the phrase "100-day cough".[2] The cough may be so hard that it causes vomiting, rib fractures, and fatigue.[3] Children less than one year old may have little or no cough and instead have periods when they cannot breathe.[4] The incubation period is usually seven to ten days. Disease may occur in those who have been vaccinated, but symptoms are typically milder.[4]

Pertussis is caused by the bacterium Bordetella pertussis, which is spread easily through the coughs and sneezes of an infected person.[5] [6] People are infectious from the start of symptoms until about three weeks into the coughing fits.[7] Diagnosis is by collecting a sample from the back of the nose and throat. This sample can then be tested either by culture or by polymerase chain reaction.[8]

Prevention is mainly by vaccination with the pertussis vaccine.[9] Initial immunization is recommended between six and eight weeks of age, with four doses to be given in the first two years of life.[10] Protection from pertussis decreases over time, so additional doses of vaccine are often recommended for older children and adults.[11] Vaccination during pregnancy is highly effective at protecting the infant from pertussis during their vulnerable early months of life, and is recommended in many countries.[12] Antibiotics may be used to prevent the disease in those who have been exposed and are at risk of severe disease.[13] In those with the disease, antibiotics are useful if started within three weeks of the initial symptoms, but otherwise have little effect in most people.[7] In pregnant women and children less than one year old, antibiotics are recommended within six weeks of symptom onset.[7] Antibiotics used include erythromycin, azithromycin, clarithromycin, or trimethoprim/sulfamethoxazole.[7] Evidence to support interventions for the cough, other than antibiotics, is poor.[14] About 50% of infected children less than a year old require hospitalization and nearly 0.5% (1 in 200) die.[4] [3]

An estimated 16.3 million people worldwide were infected in 2015.[15] Most cases occur in the developing world, and people of all ages may be affected.[9] [14] In 2015, pertussis resulted in 58,700 deaths – down from 138,000 deaths in 1990.[16] [17] Outbreaks of the disease were first described in the 16th century. The bacterium that causes the infection was discovered in 1906. The pertussis vaccine became available in the 1940s.[18]

Signs and symptoms

The classic symptoms of pertussis are a paroxysmal cough, inspiratory whoop, and fainting, or vomiting after coughing.[19] The cough from pertussis has been documented to cause subconjunctival hemorrhages, rib fractures, urinary incontinence, hernias, and vertebral artery dissection.[19] Violent coughing can cause the pleura to rupture, leading to a pneumothorax. Vomiting after a coughing spell or an inspiratory whooping sound on coughing almost doubles the likelihood that the illness is pertussis. The absence of a paroxysmal cough or posttussive emesis, though, makes it almost half as likely.[19]

The illness usually starts with mild respiratory symptoms include mild coughing, sneezing, or a runny nose (known as the catarrhal stage). After one or two weeks, the coughing classically develops into uncontrollable fits, sometimes followed by a high-pitched "whoop" sound, as the person tries to inhale. About 50% of children and adults "whoop" at some point in diagnosed pertussis cases during the paroxysmal stage.

This stage usually lasts up to 3 months, or sometimes longer. A gradual transition then occurs to the convalescent stage, which usually lasts one to four weeks. This stage is marked by a decrease in paroxysms of coughing, although paroxysms may occur with subsequent respiratory infection for many months after the onset of pertussis.[20]

Symptoms of pertussis can be variable, especially between immunized and non-immunized people. Those that are immunized can present with a more mild infection; they may only have the paroxysmal cough for a couple of weeks, and it may lack the "whooping" characteristic.[21] Although immunized people have a milder form of the infection, they can spread the disease to others who are not immune.

Incubation period

The time between exposure and the development of symptoms is on average 7–14 days (range 6–20 days),[22] rarely as long as 42 days.[23]

Cause

Pertussis is caused by the bacterium Bordetella pertussis. It is an airborne disease (through droplets) that spreads easily through the coughs and sneezes of an infected person.[5]

Host species

Humans are the only host species of B. pertussis.[24] Outbreaks of whooping cough have been observed among chimpanzees in a zoo, and among wild gorillas; in both cases it is considered likely that the infection was acquired as a result of close contact with humans.[25] [26] Several zoos have a long-standing custom of vaccinating their primates against whooping cough.[27]

Mechanism

After the bacteria are inhaled, they initially adhere to the ciliated epithelium in the nasopharynx. Surface proteins of B. pertussis, including filamentous hemaglutinin and pertactin, mediate attachment to the epithelium. The bacteria then multiply.[28] [29] In infants, who experience more severe disease, the bacteria spread down to the lungs.[29]

The bacteria secretes a number of toxins. Tracheal cytotoxin (TCT), a fragment of peptidoglycan, kills ciliated epithelial cells in the airway and thereby inhibits the mechanism which clears the airways of mucus and debris.[30] TCT may contribute to the cough characteristic of pertussis.[31] Pertussis toxin causes lymphocytosis by an unknown mechanism. The elevated number of white blood cells leads to pulmonary hypertension, a major cause of death by pertussis.[30] [29] In infants who develop encephalopathy, cerebral hemorrhage and cortical atrophy occur, likely due to hypoxia.[29]

Diagnosis

Based on symptoms

A physician's overall impression is most effective in initially making the diagnosis. Single factors are much less useful.[32] In adults with a cough of less than 8 weeks, vomiting after coughing or a "whoop" is supportive.[33] If there are no bouts of coughing or there is a fever the diagnosis is unlikely.[33] In children who have a cough of less than 4 weeks vomiting after coughing is somewhat supportive but not definitive.[33]

Lab tests

Methods used in laboratory diagnosis include culturing of nasopharyngeal swabs on a nutrient medium (Bordet–Gengou medium), polymerase chain reaction (PCR), direct fluorescent antibody (DFA), and serological methods (e.g. complement fixation test).[34] The bacteria can be recovered from the person only during the first three weeks of illness, rendering culturing and DFA useless after this period, although PCR may have some limited usefulness for an additional three weeks.

Serology may be used for adults and adolescents who have already been infected for several weeks to determine whether antibody against pertussis toxin or another virulence factor of B. pertussis is present at high levels in the blood of the person.[35]

Differential diagnosis

A similar, milder disease is caused by B. parapertussis.[36]

Prevention

The primary method of prevention for pertussis is vaccination.[37] Evidence is insufficient to determine the effectiveness of antibiotics in those who have been exposed, but are without symptoms.[38] Preventive antibiotics, however, are still frequently used in those who have been exposed and are at high risk of severe disease (such as infants).[9]

Vaccine

Pertussis vaccines are effective at preventing illness and are recommended for routine use by the World Health Organization[39] and the United States Centers for Disease Control and Prevention.[40] The vaccine saved an estimated half a million lives in 2002.[39]

The multicomponent acellular pertussis vaccine is 71–85% effective, with greater effectiveness against more severe strains.[41] However, despite widespread vaccination, pertussis has persisted in vaccinated populations and is today "one of the most common vaccine-preventable diseases in Western countries". The 21st-century resurgences in pertussis infections is attributed to a combination of waning immunity and bacterial mutations that elude vaccines.[42] [43]

Immunization does not confer lifelong immunity; a 2011 CDC study indicated that protection may only last three to six years. This covers childhood, which is the time of greatest exposure and greatest risk of death from pertussis.[19] [44]

An effect of widespread immunization on society has been the shift of reported infections from children aged 1–9 years to infants, adolescents, and adults, with adolescents and adults acting as reservoirs for B. pertussis and infecting infants who have had fewer than three doses of vaccine.[45]

Infection induces incomplete natural immunity that wanes over time.[46] A 2005 study said estimates of the duration of infection-acquired immunity range from 7 to 20 years and the different results could be the result of differences in levels of circulating B. pertussis, surveillance systems, and case definitions used. The study said protective immunity after vaccination wanes after 4–12 years.[47] One study suggested that the availability of vaccine exemptions increases the number of pertussis cases.[48]

Some studies have suggested that while acellular pertussis vaccines are effective at preventing the disease, they have a limited impact on infection and transmission, meaning that vaccinated people could spread pertussis even though they may have only mild symptoms or none at all.[49] [50] Pertussis infection in these persons may be asymptomatic, or present as illness ranging from a mild cough to classic pertussis with persistent cough (i.e., lasting more than 7 days). Even though the disease may be milder in older persons, those who are infected may transmit the disease to other susceptible persons, including unimmunized or incompletely immunized infants. Older persons are often found to have the first case in a household with multiple pertussis cases, and are often the source of infection for children.

Treatment

The antibiotics erythromycin, clarithromycin, or azithromycin are typically the recommended treatment.[38] Newer macrolides are frequently recommended due to lower rates of side effects.[9] Trimethoprim-sulfamethoxazole (TMP/SMX) may be used in those with allergies to first-line agents or in infants who have a risk of pyloric stenosis from macrolides.[9]

A reasonable guideline is to treat people age >1 year within 3 weeks of cough onset and infants age <1 year and pregnant women within 6 weeks of cough onset. If the person is diagnosed late, antibiotics will not alter the course of the illness, and even without antibiotics, they should no longer be spreading pertussis.[9] When used early, antibiotics decrease the duration of infectiousness, and thus prevent spread.[9] Short-term antibiotics (azithromycin for 3–5 days) are as effective as long-term treatment (erythromycin 10–14 days) in eliminating B. pertussis with fewer and less severe side effects.[38]

People with pertussis are most infectious during the first two weeks following the onset of symptoms.[51]

Effective treatments of the cough associated with this condition have not been developed.[52] The use of over the counter cough medications is discouraged and has not been found helpful.

Prognosis

While most healthy older children and adults fully recover, infection in newborns is particularly severe. Pertussis is fatal in an estimated 0.5% of US infants under one year of age.[53] First-year infants are also more likely to develop complications, such as: apneas (31%), pneumonia (12%), seizures (0.6%) and encephalopathy (0.15%).[53] This may be due to the ability of the bacterium to suppress the immune system.[54]

Epidemiology

Pertussis is endemic worldwide. More than 151,000 cases were reported globally during 2018.[55] However not all cases are reported or correctly diagnosed, especially in developing countries. Pertussis is one of the leading causes of vaccine-preventable deaths worldwide.[56] A study in 2017 estimated the global burden of the disease to be 24 million cases per year with 160,000 deaths among young children, with about 90% of all cases occurring in developing countries.[57] [56]

Before vaccines, an average of 178,171 cases was reported in the U.S., with peaks reported every two to five years; more than 93% of reported cases occurred in children under 10 years of age. The actual incidence was likely much higher. After vaccinations were introduced in the 1940s, pertussis incidence fell dramatically to approximately 1,000 by 1976. Incidence rates have increased since 1980. In 2015, 20,762 people were reported to have been infected in the United States.[58] Pertussis is the only vaccine-preventable disease that is associated with increasing deaths in the U.S. The number of deaths increased from four in 1996 to 17 in 2001, almost all of which were infants under one year.[59] In the U.S. pertussis in adults has increased significantly since about 2004.[60]

Epidemics of the disease occur cyclically, every three to 5 years, both in areas with vaccination programs and those without.[61] Over time, immunity declines in those who have either been vaccinated or have recovered from infection.[62] In addition, infants are born who are susceptible to infection. An epidemic can occur once herd immunity reduces below decreases below a certain level.[63] It is also possible that the bacterium is evolving to evade vaccine-induced immunity.[64]

History

Discovery

B. pertussis was discovered in 1906 by Jules Bordet and Octave Gengou, who also developed the first serology and vaccine. Efforts to develop an inactivated whole-cell vaccine began soon after B. pertussis was cultured that year. In the 1920s, Louis W. Sauer developed a weak vaccine for whooping cough at Evanston Hospital (Evanston, IL). In 1925 Danish physician Thorvald Madsen was the first to test a whole-cell vaccine on a wide scale.[65] Madsen used the vaccine to control outbreaks in the Faroe Islands in the North Sea.

Vaccine

In 1932, an outbreak of whooping cough hit Atlanta, Georgia, prompting pediatrician Leila Denmark to begin her study of the disease. Over the next six years, her work was published in the Journal of the American Medical Association, and in partnership with Emory University and Eli Lilly & Company, she developed the first pertussis vaccine.[66] In 1942, American scientists Grace Eldering, Loney Gordon, and Pearl Kendrick combined the whole-cell pertussis vaccine with diphtheria and tetanus toxoids to generate the first DTP combination vaccine.[67] To minimize the frequent side effects caused by the pertussis component, Japanese scientist Yuji Sato developed an acellular vaccine consisting of purified haemagglutinins (HAs: filamentous strep throat and leukocytosis-promoting-factor HA), which are secreted by B. pertussis. Sato's acellular pertussis vaccine was used in Japan starting in 1981.[68] Later versions of the acellular vaccine in other countries consisted of additional defined components of B. pertussis and were often part of the DTaP combination vaccine.

External links

Notes and References

  1. Web site: 2022-09-07 . Preventing Whooping Cough (Pertussis) CDC . 2023-05-21 . Centers for Disease Control . en-us.
  2. Web site: Pertussis (Whooping Cough) Fast Facts. cdc.gov. 12 February 2015. 13 February 2014. live. https://web.archive.org/web/20150207090550/http://www.cdc.gov/pertussis/fast-facts.html. 7 February 2015.
  3. Web site: 4 August 2022 . Pertussis (Whooping Cough) Complications . 26 March 2024 . Centers for Disease Control.
  4. Web site: August 4, 2022 . Pertussis (Whooping Cough) Signs & Symptoms . 26 March 2023 . Centers for Disease Control.
  5. Web site: Pertussis (Whooping Cough) Causes & Transmission. cdc.gov. 12 February 2015. 4 September 2014. live. https://web.archive.org/web/20150214040511/http://www.cdc.gov/pertussis/about/causes-transmission.html. 14 February 2015.
  6. Web site: Pertussis . 2024-03-26 . World Health Organization . en.
  7. Web site: 28 August 2013 . Pertussis (Whooping Cough) Treatment . live . https://web.archive.org/web/20150211094551/http://www.cdc.gov/pertussis/clinical/treatment.html . 11 February 2015 . 13 February 2015 . cdc.gov.
  8. Web site: Pertussis (Whooping Cough) Specimen Collection. cdc.gov. 13 February 2015. 28 August 2013. live. https://web.archive.org/web/20150208221312/http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html. 8 February 2015.
  9. Heininger U . Update on pertussis in children . Expert Review of Anti-Infective Therapy . 8 . 2 . 163–73 . February 2010 . 20109046 . 10.1586/eri.09.124 . 207217558 .
  10. Revised guidance on the choice of pertussis vaccines: July 2014 . Relevé Épidémiologique Hebdomadaire . 89 . 30 . 337–40 . July 2014 . 25072068 . https://web.archive.org/web/20150213144751/http://www.who.int/wer/2013/wer8930.pdf?ua=1 . live . 13 February 2015 .
  11. Pertussis vaccines: WHO position paper . Relevé Épidémiologique Hebdomadaire . 85 . 40 . 385–400 . October 2010 . 20939150 .
  12. Vygen-Bonnet S, Hellenbrand W, Garbe E, von Kries R, Bogdan C, Heininger U, Röbl-Mathieu M, Harder T . Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review . BMC Infect Dis . 20 . 1 . 136 . February 2020 . 32054444 . 7020352 . 10.1186/s12879-020-4824-3 . free .
  13. Web site: Pertussis (Whooping Cough) Prevention. cdc.gov. 13 February 2015. 10 October 2014. live. https://web.archive.org/web/20150208221327/http://www.cdc.gov/pertussis/clinical/prevention.html. 8 February 2015.
  14. Wang K, Bettiol S, Thompson MJ, Roberts NW, Perera R, Heneghan CJ, Harnden A . Symptomatic treatment of the cough in whooping cough . The Cochrane Database of Systematic Reviews . 9 . 9 . CD003257 . September 2014 . 25243777 . 10.1002/14651858.CD003257.pub5 . 7154224 .
  15. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1545–1602 . October 2016 . 27733282 . 5055577 . 10.1016/S0140-6736(16)31678-6 . Vos . Theo . Allen . Christine . Arora . Megha . Barber . Ryan M. . Bhutta . Zulfiqar A. . Brown . Alexandria . Carter . Austin . Casey . Daniel C. . Charlson . Fiona J. . Chen . Alan Z. . Coggeshall . Megan . Cornaby . Leslie . Dandona . Lalit . Dicker . Daniel J. . Dilegge . Tina . Erskine . Holly E. . Ferrari . Alize J. . Fitzmaurice . Christina . Fleming . Tom . Forouzanfar . Mohammad H. . Fullman . Nancy . Gething . Peter W. . Goldberg . Ellen M. . Graetz . Nicholas . Haagsma . Juanita A. . Hay . Simon I. . Johnson . Catherine O. . Kassebaum . Nicholas J. . Kawashima . Toana . Kemmer . Laura .
  16. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1459–1544 . October 2016 . 27733281 . 5388903 . 10.1016/s0140-6736(16)31012-1 . Wang . Haidong . Naghavi . Mohsen . Allen . Christine . Barber . Ryan M. . Bhutta . Zulfiqar A. . Carter . Austin . Casey . Daniel C. . Charlson . Fiona J. . Chen . Alan Zian . Coates . Matthew M. . Coggeshall . Megan . Dandona . Lalit . Dicker . Daniel J. . Erskine . Holly E. . Ferrari . Alize J. . Fitzmaurice . Christina . Foreman . Kyle . Forouzanfar . Mohammad H. . Fraser . Maya S. . Fullman . Nancy . Gething . Peter W. . Goldberg . Ellen M. . Graetz . Nicholas . Haagsma . Juanita A. . Hay . Simon I. . Huynh . Chantal . Johnson . Catherine O. . Kassebaum . Nicholas J. . Kinfu . Yohannes . Kulikoff . Xie Rachel .
  17. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet . 385 . 9963 . 117–71 . January 2015 . 25530442 . 4340604 . 10.1016/S0140-6736(14)61682-2 . ((GBD 2013 Mortality Causes of Death Collaborators)) .
  18. Book: Atkinson. William . Pertussis Epidemiology and Prevention of Vaccine-Preventable Diseases. May 2012. Public Health Foundation. 978-0-9832631-3-5. 215–230. 12th. live. https://web.archive.org/web/20170729141728/https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html. 29 July 2017.
  19. Cornia PB, Hersh AL, Lipsky BA, Newman TB, Gonzales R . Does this coughing adolescent or adult patient have pertussis? . JAMA . 304 . 8 . 890–6 . August 2010 . 20736473 . 10.1001/jama.2010.1181 . 14430946 .
  20. Web site: Pink book | Pertussis | Epidemiology of Vaccine-Preventable Diseases | CDC. 2 March 2019.
  21. Nguyen. Van Tuong Ngoc. Simon. Lauren. 1 September 2018. Pertussis: The Whooping Cough. Primary Care: Clinics in Office Practice. Infectious Disease. 45. 3. 423–431. 10.1016/j.pop.2018.05.003. 30115332. 240275364 . 0095-4543.
  22. Heymann, David L. (ed): Pertussis; in Control of Communicable Diseases Manual. p. 457. American Public Health Association, Washington DC, 2008,
  23. Web site: Pertussis (whooping cough) . New York State Department of Health . 8 June 2013 . live . https://web.archive.org/web/20130722133222/http://www.health.ny.gov/diseases/communicable/pertussis/fact_sheet.htm . 22 July 2013 .
  24. Web site: 2018-06-29 . 15.3E: Whooping Cough . 2024-03-29 . Biology LibreTexts . en.
  25. Gustavsson OE, Röken BO, Serrander R . An epizootic of whooping cough among chimpanzees in a zoo . Folia Primatologica; International Journal of Primatology . 55 . 1 . 45–50 . 1990 . 2394416 . 10.1159/000156498 .
  26. Palacios . Gustavo . Lowenstine . Linda J. . Cranfield . Michael R. . Gilardi . Kirsten V. K. . Spelman . Lucy . Lukasik-Braum . Magda . Kinani . Jean-Felix . Mudakikwa . Antoine . Nyirakaragire . Elisabeth . Bussetti . Ana Valeria . Savji . Nazir . Hutchison . Stephen . Egholm . Michael . Lipkin . W. Ian . April 2011 . Human Metapneumovirus Infection in Wild Mountain Gorillas, Rwanda . Emerging Infectious Diseases . en-us . 17 . 4 . 711–713 . 10.3201/eid1704.100883 . 3377396 . 21470468.
  27. Book: Loomis MR . Immunoprofylaxis in infant great apes . Graham CE, Bowen JA . Monographs in Primatology . 5 . Clinical Management of Infant Great Apes . 107–112 . Liss . New York . 1985.
  28. Book: Top. Karina A.. Halperin. Scott A.. Kasper. Dennis L.. Fauci. Anthony S. . Harrison's Infectious Diseases. 2017. McGraw-Hill Education. New York. 978-1-259-83597-1. 502–506. 3. Pertussis and other Bordetella infections.
  29. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ . Pertussis: Microbiology, Disease, Treatment, and Prevention . Clinical Microbiology Reviews . 29 . 3 . 449–86 . July 2016 . 27029594 . 4861987 . 10.1128/CMR.00083-15 .
  30. Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP, Stibitz ES . Pertussis pathogenesis—what we know and what we don't know . The Journal of Infectious Diseases . 209 . 7 . 982–5 . April 2014 . 24626533 . 3952676 . 10.1093/infdis/jit639 .
  31. Melvin JA, Scheller EV, Miller JF, Cotter PA . Bordetella pertussis pathogenesis: current and future challenges . Nature Reviews. Microbiology . 12 . 4 . 274–88 . April 2014 . 24608338 . 4205565 . 10.1038/nrmicro3235 .
  32. Ebell MH, Marchello C, Callahan M . Clinical Diagnosis of Bordetella Pertussis Infection: A Systematic Review . Journal of the American Board of Family Medicine . 30 . 3 . 308–319 . 2017 . 28484063 . 10.3122/jabfm.2017.03.160330 . free .
  33. Moore A, Harnden A, Grant CC, Patel S, Irwin RS . Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report . Chest . 155 . 1 . 147–154 . January 2019 . 30321509 . 6859243 . 10.1016/j.chest.2018.09.027 .
  34. Book: Pedro-Pons, Agustín. Patología y Clínica Médicas. 1968. 3rd. 615. 6. Salvat. 84-345-1106-1. es. Barcelona.
  35. Web site: Pertussis. Euro Diagnostica. Euro Diagnostica AB. 29 February 2016. live. https://web.archive.org/web/20160304231237/http://www.eurodiagnostica.com/index.php?headId=4&pageId=4&langId=1&diseaseId=8#nr1-tab. 4 March 2016.
  36. Book: Finger H, von Koenig CH . Bordetella–Clinical Manifestations. In: Barron's Medical Microbiology . Baron S . etal . 4th . Univ of Texas Medical Branch . 1996 . https://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.1694 . 0-9631172-1-1 . live . https://web.archive.org/web/20071014175713/http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.section.1694 . 14 October 2007 . Bordetella . 21413270 .
  37. Web site: Pertussis Whooping Cough Vaccination CDC. www.cdc.gov. 27 May 2017. live. https://web.archive.org/web/20170526025248/https://www.cdc.gov/pertussis/vaccines.html. 26 May 2017.
  38. Altunaiji S, Kukuruzovic R, Curtis N, Massie J . Antibiotics for whooping cough (pertussis) . The Cochrane Database of Systematic Reviews . 3 . CD004404 . July 2007 . 17636756 . 10.1002/14651858.CD004404.pub3 . 11322855 .
  39. Web site: Annex 6 whole cell pertussis. World Health Organization. 5 June 2011. live. https://web.archive.org/web/20120324184124/http://www.who.int/biologicals/publications/trs/areas/vaccines/whole_cell_pertussis/Annex%206%20whole%20cell%20pertussis.pdf. 24 March 2012.
  40. Web site: Pertussis: Summary of Vaccine Recommendations. Centers for Disease Control and Prevention. 5 June 2011. live. https://web.archive.org/web/20110629042921/http://www.cdc.gov/vaccines/vpd-vac/pertussis/recs-summary.htm. 29 June 2011.
  41. Zhang L, Prietsch SO, Axelsson I, Halperin SA . Acellular vaccines for preventing whooping cough in children . The Cochrane Database of Systematic Reviews . 2014 . 9 . CD001478 . September 2014 . 25228233 . 10.1002/14651858.CD001478.pub6 . 9722541 .
  42. Mooi FR, Van Der Maas NA, De Melker HE . Pertussis resurgence: waning immunity and pathogen adaptation – two sides of the same coin . Epidemiology and Infection . 142 . 4 . 685–94 . April 2014 . 23406868 . 10.1017/S0950268813000071 . Oxford University Press . 9151166 . 206283573 .
  43. van der Ark AA, Hozbor DF, Boog CJ, Metz B, van den Dobbelsteen GP, van Els CA . Resurgence of pertussis calls for re-evaluation of pertussis animal models . Expert Review of Vaccines . 11 . 9 . 1121–37 . September 2012 . 23151168 . 10.1586/erv.12.83 . 10457474 .
  44. Versteegh FG, Schellekens JF, Fleer A, Roord JJ . Pertussis: a concise historical review including diagnosis, incidence, clinical manifestations and the role of treatment and vaccination in management . Rev Med Microbiol . 2005 . 16 . 3 . 79–89 . 10.1097/01.revmedmi.0000175933.85861.4e. 71775827 .
  45. Mattoo S, Cherry JD . Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies . Clinical Microbiology Reviews . 18 . 2 . 326–82 . April 2005 . 15831828 . 1082800 . 10.1128/CMR.18.2.326-382.2005 .
  46. Book: Disease Control Priorities in Developing Countries. 2nd. 2006. Jamison DT, Breman JG, Measham AR. etal. Vaccine-Preventable Diseases. Brenzel L, Wolfson LJ, Fox-Rushby J. etal. Table 20.1 Selected Vaccine-preventable Diseases and Vaccines. https://www.ncbi.nlm.nih.gov/books/NBK11768/. International Bank for Reconstruction and Development, World Bank. Washington DC. 21250343. 978-0-8213-6179-5.
  47. Wendelboe AM, Van Rie A, Salmaso S, Englund JA . Duration of immunity against pertussis after natural infection or vaccination . The Pediatric Infectious Disease Journal . 24 . 5 Suppl . S58-61 . May 2005 . 15876927 . 10.1097/01.inf.0000160914.59160.41 . 45434262 . free .
  48. Yang YT, Debold V . A longitudinal analysis of the effect of nonmedical exemption law and vaccine uptake on vaccine-targeted disease rates . American Journal of Public Health . 104 . 2 . 371–7 . February 2014 . 24328666 . 3935668 . 10.2105/AJPH.2013.301538 .
  49. Srugo I, Benilevi D, Madeb R, Shapiro S, Shohat T, Somekh E, Rimmar Y, Gershtein V, Gershtein R, Marva E, Lahat N . Pertussis infection in fully vaccinated children in day-care centers, Israel . Emerging Infectious Diseases . 6 . 5 . 526–9 . October 2000 . 10998384 . 10.3201/eid0605.000512 . dmy-all . 2627963 .
  50. Web site: Pertussis Vaccines:WHO Position Paper . August 2015 . It is plausible that in humans, as in nonhuman primates, asymptomatic or mildly symptomatic infections in DTaP-immunized persons may result in transmission of B. pertussis to others and may drive pertussis outbreaks. . live . https://web.archive.org/web/20160304110610/http://www.who.int/wer/2015/wer9035.pdf . 4 March 2016 .
  51. Web site: Pertussis Whooping Cough Causes and Transmission CDC. 1 February 2019. www.cdc.gov. en-us. 24 April 2020.
  52. Wang K, Bettiol S, Thompson MJ, Roberts NW, Perera R, Heneghan CJ, Harnden A . Symptomatic treatment of the cough in whooping cough . The Cochrane Database of Systematic Reviews . 9 . 9 . CD003257 . September 2014 . 25243777 . 10.1002/14651858.CD003257.pub5 . 7154224 .
  53. Web site: Pertussis: Complications . . 24 August 2012 . live . https://web.archive.org/web/20120814112442/http://www.cdc.gov/pertussis/about/complications.html . 14 August 2012 .
  54. Carbonetti NH . Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools . Future Microbiology . 5 . 3 . 455–69 . March 2010 . 20210554 . 2851156 . 10.2217/fmb.09.133 .
  55. Web site: Pertussis . 2024-03-26 . World Health Organization . en.
  56. Web site: Pertussis in Other Countries . live . https://web.archive.org/web/20130512041451/http://www.cdc.gov/pertussis/countries.html . 12 May 2013 . 30 July 2024 . Centers for Disease Control and Prevention (CDC).
  57. Yeung . Karene Hoi Ting . Duclos . Philippe . Nelson . E. Anthony S. . Hutubessy . Raymond Christiaan W. . September 2017 . An update of the global burden of pertussis in children younger than 5 years: a modelling study . The Lancet. Infectious Diseases . 17 . 9 . 974–980 . 10.1016/S1473-3099(17)30390-0 . 1474-4457 . 28623146.
  58. Web site: Pertussis Whooping Cough Surveillance Cases by Year CDC. www.cdc.gov. 10 April 2017. live. https://web.archive.org/web/20170410214238/https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html. 10 April 2017.
  59. Gregory DS . Pertussis: a disease affecting all ages . American Family Physician . 74 . 3 . 420–6 . August 2006 . 16913160 . https://web.archive.org/web/20080516080021/http://www.aafp.org/afp/20060801/420.html . live . 16 May 2008 .
  60. News: Enduring and Painful, Pertussis Leaps Back. Kate Murphy. The New York Times. 22 February 2005. live. https://web.archive.org/web/20130524191616/http://www.nytimes.com/2005/02/22/health/22cough.html. 24 May 2013.
  61. Bouchez . Valérie . Guiso . Nicole . October 2015 . Carbonetti . Nicholas . Bordetella pertussis, B. parapertussis, vaccines and cycles of whooping cough . Pathogens and Disease . en . 73 . 7 . ftv055 . 10.1093/femspd/ftv055 . 26242280 . 2049-632X.
  62. Burdin . Nicolas . Handy . Lori Kestenbaum . Plotkin . Stanley A. . December 2017 . What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines . Cold Spring Harbor Perspectives in Biology . en . 9 . 12 . a029454 . 10.1101/cshperspect.a029454 . 1943-0264 . 5710106 . 28289064.
  63. Web site: 15 March 2017 . Facts and figures - Whooping cough . 2024-03-26 . NSW Health . en.
  64. Web site: 2022-06-14 . Pertussis (whooping cough) - Epidemic Control Toolkit . 26 March 2024 . The International Federation of Red Cross.
  65. Baker JP, Katz SL . Childhood vaccine development: an overview . Pediatric Research . 55 . 2 . 347–56 . February 2004 . 14630981 . 10.1203/01.PDR.0000106317.36875.6A . free .
  66. Web site: Changing the Face of Medicine Dr. Leila Alice Daughtry Denmark. www.nlm.nih.gov. 3 February 2016. live. https://web.archive.org/web/20150321042123/http://www.nlm.nih.gov/changingthefaceofmedicine/physicians/biography_78.html. 21 March 2015.
  67. Web site: Bannink . Jill . Finding aid for the Michigan women and the whooping cough vaccine collection[s] ]. live . https://web.archive.org/web/20150205095413/http://grplpedia.grpl.org/wiki/images/6/65/328.pdf . 5 February 2015 .
  68. Sato Y, Kimura M, Fukumi H . Development of a pertussis component vaccine in Japan . Lancet . 1 . 8369 . 122–6 . January 1984 . 6140441 . 10.1016/S0140-6736(84)90061-8 . 23621152 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Whooping cough".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.